A late Christmas present for Allogene
US clinical hold over Allogene’s entire pipeline has just been lifted.
Crispr’s reminder about allogeneic Car-T redosing
Crispr follows Allogene with backing for off-the-shelf Car-T therapy – and adds big concerns over lack of durability.
Allogene raises the spectre of a Car-T nightmare
Little is known about yesterday’s clinical hold on Allogene’s entire pipeline, but chromosomal abnormalities hint at a worst-case scenario.
Asco 2021 – off-the-shelf cell therapy inches towards reality
After years of waiting, courtesy of Allogene investors at last have an allogeneic Car-T dataset comparable with autologous therapies.
Precision’s itinerant Car-T cells go on another journey
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Ash 2020 cell therapy preview – the battle for recognition
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.